PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q34587249

about

Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints Recent advances in the management of Hodgkin lymphoma Customized targeted therapy in Hodgkin lymphoma: hype or hope?Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lymphoma: immune evasion strategies MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells.The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignancies Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.Immunological deregulation in classic hodgkin lymphoma.Tim-3 and its role in regulating anti-tumor immunity.Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.Chronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression.The molecular pathogenesis of Hodgkin lymphoma.Hodgkin lymphoma.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.T cell metabolic fitness in antitumor immunity.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.T-cell exhaustion in the tumor microenvironment.

P2860

Q26744527-5322D879-97C4-422F-A1A3-F675EFB19C4C Q26745842-C189495B-01F8-452E-A59D-518D256BC318 Q26751214-D8E5DC16-1420-482D-B737-5FF16A16A782 Q27002554-52F684AF-61FD-4793-92DF-7F25F0A43B36 Q27011510-0957D305-0BC6-48B1-8F33-87FE216E7D19 Q28076071-8EF36D22-78D2-4F1C-86BF-030B4C2999B6 Q28080705-07C0C957-C0F3-4F5D-8B0D-FBACE151988F Q28306431-FF420C9A-6F52-4DB6-A068-A9699E1D7FF1 Q30560427-E6C79AAB-0AE2-42A8-B62F-2948429D1F9E Q33597192-DFD05C9A-609C-49CA-8BA0-276204B3C303 Q33632062-41A7A423-60DE-4CC5-B61D-6CDD8C0163A1 Q33638083-7D6450A6-C453-4EAA-91C6-44DD31B6EB68 Q33651495-3A8726F3-02C7-43F5-A0E7-69CC19C62AD3 Q33704061-58009689-C5FA-4A83-B896-998F318DC218 Q33738783-0579F1A5-B6DF-4364-8DB0-226FE74D0235 Q33754618-5C0AD8CA-FCD2-449B-BE8B-67ED635B4B3D Q33778391-7CB026CC-3C26-480B-9196-9FF57813A675 Q33909020-AC8752CA-7F73-4816-8C4B-4570090FC0BD Q34017748-93829398-B16D-4807-B612-8E3F79043900 Q34141476-9D6015F8-43F8-411B-AB5E-58CE87478463 Q34161493-504C3049-C4CC-40F8-84A1-70B06683593C Q34235750-E5E708B9-9E0B-404A-851E-AE59C191FD86 Q34240314-11C5F54F-9096-40A0-BA2F-91AF007736E3 Q34245048-2850E0E8-2BED-4DD5-852B-AB35E5671BBE Q34245299-956332CC-9E9D-4A58-8E88-A95308CAC39B Q34505107-F8C3FCFC-6E21-40E2-BF19-84DA581974AC Q34626576-4461CD5B-64CF-421A-9ED3-D378C06CA593 Q34643277-C7127521-E8C8-4C83-A41F-AE7569823F51 Q34648812-5335BFAB-5307-49AC-8A8E-94BAAB77C8B3 Q34707183-3F027A9D-10AF-464C-80E4-DD655A51CA63 Q34801069-4DD4E694-2960-40F4-8EB8-F742F0D7D961 Q34997704-5387AB64-D843-4EEE-8F04-C1419C9DA4C3 Q35044301-880BBFAB-0780-4E37-B709-7599ADF45C44 Q35244289-D0B0ABE8-50A9-4CD4-9243-4E7B9068F646 Q35371293-3C541957-104D-4BB9-BF58-A9E6F3B8D7BD Q35422283-A7EBBCB9-2900-48C2-B259-1749BBCB21E6 Q35664956-00410CCD-AC61-4D6E-A9B1-A91917692BAA Q35875897-B0DC7640-AEBD-456D-A4CD-CC69A17B1E9C Q36118020-71351619-06BF-4DFF-AE89-1D79CB3A9CBA Q36347369-DF99F97C-AC1C-4E43-AB1C-D2B2ED2DA1E3

P2860

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q34587249

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@ast

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@en

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@nl

type

label

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@ast

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@en

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@nl

prefLabel

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@ast

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@en

PD-1-PD-1 ligand interaction c ...... vironment of Hodgkin lymphoma.

@nl

P1433

Q34587249-8495ECB2-3AB2-4C17-8EC6-5C6557953628

P1476

Q34587249-EB27A141-60ED-499E-91E9-D54E421FC1AF

P2093

Q34587249-1D2E562B-A07D-43C1-A87C-7C6AAC26B464

Q34587249-2731EFFE-DFC1-42CE-9DA8-03D3A33106A6

Q34587249-39895CFD-2D01-4FF5-AF91-6F80CB6A17D2

Q34587249-63E399A7-BBB4-4415-A79A-A005BBC3E2B8

Q34587249-8C798F01-7492-4D0A-8110-AE661FBC4B6C

Q34587249-9FBDDE4F-17E6-4DB4-9718-D8D3F69F6BE0

Q34587249-ACA9A97B-19DE-434D-9115-4EC5F9A8FD6B

Q34587249-E39F5657-F14F-4769-8886-4F805C83B296

Q34587249-F2D7E84F-9BC8-409A-AAD3-D8115E04D2DE

Q34587249-FF84429E-43F4-4C0D-A572-2229622F15B8

P304

Q34587249-D1EAA839-7348-4FDA-A33F-51A7BF77F806

P31

Q34587249-FD822F90-8580-48D1-B370-802C9699D19E

P356

Q34587249-48F1DF65-7BE0-49BC-837B-DC44D2A2265C

P407

Q34587249-88DEAB32-A834-407C-A949-4D0416CA0BED

P433

Q34587249-EBE7E3FE-91C0-4EC3-86ED-0EBB7D192BE3

P478

Q34587249-F01F4BDE-B971-4961-B421-4C319DEBC55E

P50

Q34587249-F5C52641-C182-452A-A20E-D980F39E33F9

P577

Q34587249-3FF13026-BAA2-4447-8473-6187B1FAD056

P5875

Q34587249-97F1D100-5626-4DE6-BAD4-4EC1BA59FE1E

P698

Q34587249-6CD6AD52-98DB-48E4-A683-A4B69017F0B2

P356

BLOOD-2007-05-085159

P1433

P1476

PD-1-PD-1 ligand interaction c ...... nvironment of Hodgkin lymphoma

@en

P2093

Masaharu Tashima

http://www.w3.org/2001/XMLSchema#string

Masakatsu Hishizawa

http://www.w3.org/2001/XMLSchema#string

Masayuki Kurata

http://www.w3.org/2001/XMLSchema#string

Momoko Nishikori

http://www.w3.org/2001/XMLSchema#string

Ryo Yamamoto

http://www.w3.org/2001/XMLSchema#string

Tadakazu Kondo

http://www.w3.org/2001/XMLSchema#string

Takamasa Hayashi

http://www.w3.org/2001/XMLSchema#string

Takashi Uchiyama

http://www.w3.org/2001/XMLSchema#string

Tomomi Sakai

http://www.w3.org/2001/XMLSchema#string

Toshio Kitawaki

http://www.w3.org/2001/XMLSchema#string

P304

3220-3224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-05-085159

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Katsuyuki Ohmori

P577

2008-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5647567

http://www.w3.org/2001/XMLSchema#string

P698

18203952

http://www.w3.org/2001/XMLSchema#string